Organon and Henlius Launch Denosumab Biosimilars in Canada
Event summary
- Organon Canada and Henlius launched BILDYOS® and TUZEMTY®, biosimilars to PROLIA and XGEVA, in Canada on June 23, 2026.
- The products are approved for all indications of the reference treatments, including osteoporosis and cancer-related bone events.
- Organon holds exclusive commercialization rights under a 2022 license agreement with Henlius, excluding China.
- Henlius has achieved regulatory approvals for 10 products across over 60 countries as of early 2026.
The big picture
This launch strengthens Organon's biosimilars portfolio, reinforcing its commitment to expanding treatment options in Canada. The partnership with Henlius aligns with broader industry trends toward cost-effective biologic therapies and global healthcare access. With Henlius advancing into its 'Globalisation 2.0' phase, the collaboration could set a precedent for future biosimilar commercialization strategies.
What we're watching
- Market Penetration
- How quickly BILDYOS® and TUZEMTY® gain market share against established denosumab treatments in Canada.
- Cost Impact
- Whether the introduction of biosimilars will significantly reduce healthcare costs for osteoporosis treatments.
- Global Expansion
- The pace at which Organon and Henlius expand their biosimilar collaboration to other international markets.
Related topics